A Phase 2 interventional study of E7080 and Comparator Drug in Solid Tumors, sponsored by Eisai Inc.. Completed at 28 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
This is an open-label extension study to roll-over eligible participants from Eisai-sponsored lenvatinib studies. The participants may roll-over no sooner than the primary completion dates in their parent study or after all study data for the primary outcome measure have been collected for the parent study. The parent study is defined as the Eisai-sponsored lenvatinib clinical study in which the participant was receiving lenvatinib either as monotherapy or as combination therapy or was receiving any other comparator therapy. The participant can be enrolled in the current study for the purpose of long-term safety data collection if all the selection criteria for the current study are met. The intention is that the participant will not be without study drug during the transition from the parent study to the rollover study.
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
It is required for all participants currently participating in other lenvatinib studies to meet the following eligibility criteria.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
Drug: E7080
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
Drug: E7080 · Drug: Comparator Drug
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo. For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo.
Drug: Comparator Drug · Drug: Comparator Drug: Sorafenib
Oral Administration.
Also known as: lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate
Per parent study.
Per parent study.
Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)
A treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study informed consent form (ICF), or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the mentioned criteria.
Time frame: Up to 58.8 months in current study
Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study in ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A non-serious TEAE was any AE that was not considered a serious adverse event.
Time frame: Up to 58.8 months in current study
Number of Participants With Treatment-Related TEAEs
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. Related TEAE was defined as AE with causal relationship between the study drug and the TEAE.
Time frame: Up to 58.8 months in current study
Number of Participants With Any TEAE
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous.
Time frame: Up to 58.8 months in current study
Participants took part in the study at 28 investigative sites in China, United States, Australia, Belgium, Germany, Italy, South Korea, Netherlands, Poland, Romania, and Thailand from 16 August 2018 to 21 December 2023.
| Milestone | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| Started | 19 | 21 |
| Completed | 0 | 0 |
| Not completed | 19 | 21 |
| Withdrew: Unable to travel due to covid-19 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Transitioned to commercial drug | 6 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Disease progression | 7 | 7 |
A treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study informed consent form (ICF), or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the mentioned criteria.
| Participants | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs) | 7 | 14 |
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study in ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A non-serious TEAE was any AE that was not considered a serious adverse event.
| Participants | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs) | 18 | 17 |
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. Related TEAE was defined as AE with causal relationship between the study drug and the TEAE.
| Participants | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| Number of Participants With Treatment-Related TEAEs | 15 | 14 |
A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous.
| Participants | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| Number of Participants With Any TEAE | 18 | 20 |
Collected over Up to 58.8 months in current study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A, China: Lenvatinib Monotherapy | 2/19 (10.5%) | 7/19 (36.8%) | 18/19 (94.7%) |
| Cohort A, Rest of the World: Lenvatinib Monotherapy | 5/21 (23.8%) | 14/21 (66.7%) | 17/21 (81%) |
| Event | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 1/19 | 2/21 |
| Urinary tract infectionInfections and infestations | 0/19 | 2/21 |
| Large intestine polypGastrointestinal disorders | 1/19 | 0/21 |
| COVID-19Infections and infestations | 1/19 | 1/21 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/19 | 0/21 |
| Bone painMusculoskeletal and connective tissue disorders | 1/19 | 0/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/19 | 0/21 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/19 | 0/21 |
| HypoaesthesiaNervous system disorders | 1/19 | 0/21 |
| SeizureNervous system disorders | 1/19 | 0/21 |
| Event | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy |
|---|---|---|
| ProteinuriaRenal and urinary disorders | 6/19 | 1/21 |
| Weight decreasedInvestigations | 0/19 | 5/21 |
| COVID-19Infections and infestations | 4/19 | 0/21 |
| Alanine aminotransferase increasedInvestigations | 4/19 | 1/21 |
| Aspartate aminotransferase increasedInvestigations | 4/19 | 1/21 |
| AlbuminuriaRenal and urinary disorders | 4/19 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 3/19 | 4/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/19 | 4/21 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 3/19 | 0/21 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 3/19 | 0/21 |
Safety analysis set included the group of participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy | Total |
|---|---|---|---|
| Mean | 56.2 ± 8.17 | 62.7 ± 11.45 | 59.6 ± 10.42 |
| Sex: Female, Male(Participants) | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy | Total |
|---|---|---|---|
| Female | 9 | 12 | 21 |
| Male | 10 | 9 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 19 | 21 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A, China: Lenvatinib Monotherapy | Cohort A, Rest of the World: Lenvatinib Monotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 19 | 4 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 17 | 17 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Dec 2023, 64 months.
Results were first posted in Jan 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Sorafenib